A B S T R A C T The role of the renin-angiotensin system in the regulation of the systemic and coronary circulations during sodium depletion was studied in conscious normotensive dogs by i.v. administration of teprotide (0.5 mg/kg), an angiotensin-converting enzyme inhibitor, and saralasin (0.05-5 ,ug/kg per min), an angiotensin-receptor antagonist. Sodium depletion was produced by administering a low sodium diet and furosemide for 5 days. Administration of both teprotide and saralasin lowered systemic arterial blood pressure and total peripheral vascular resistance. Simultaneously, cardiac output increased, but left ventricular end-diastolic pressure, dP/dt, and dP/dt/P did not change significantly. Furthermore, both agents reduced diastolic coronary vascular resistance and increased coronary blood flow, but did not affect myocardial oxygen consumption, left ventricular work, or myocardial efficiency. These systemic and coronary vasodilator effects of teprotide and saralasin, however, were not observed in normal dogs on a regular sodium diet; in this group, the only effect noted was a slight increase in arterial pressure during saralasin infusion. Arterial plasma concentration of norepinephrine did not differ between normal and sodiumdepleted dogs, nor did it change significantly after teprotide administration. These results suggest that, vessels, but has no significant effects on myocardial contractility or energetics. It also appears likely that the increase in cardiac output observed in sodiumdepleted dogs after angiotensin inhibition was caused, at least in part, by the decrease in systemic arterial pressure.
INTRODUCTIONSodium depletion increases plasma renin activity (PRA)l and blood angiotensin II concentration (1-3), indicating an activation of the renin-angiotensin system. This increase in 'angiotensin II concentration probably plays an important role in the maintenance of normal arterial blood pressure during salt depletion, because the arterial blood pressure decreases under these conditions after administration of saralasin (1-sarcosine-8-alanine-angiotensin II; P113) (2-7), teprotide (SQ 20,881) (7-10), and SQ 14,225 (11). Saralasin is a competitive receptor antagonist of angiotensin II (4, 12, 13), whereas the latter two agents inhibit angiotensin-converting enzyme, which converts angiotensin I to the biologically active angiotensin II (8,(13)(14)(15)(16). Because angiotensin II is one of the most potent vasoconstrictors known (17, 18), a decrease in arterial blood pressure after angiotensin inhibition presumably is due to elimination of the angiotensin-induced vasoconstriction. However, angiotensin II also exerts a positive inotropic action on the heart (19,20), the abolition of which may lower the arterial pressure. Previous investigators (9, 10) have shown that cardiac output de-